Stock Scorecard
Stock Summary for Genmab (GMAB) - $28.47 as of 4/25/2024 1:41:19 AM EST
Total Score
14 out of 29
Currently on the following lists
None
Tim's Recommendation
Possible Buy
Growth List Algorithm Criteria for GMAB
| Positive earnings growth | |
| P/E ratio less than Industry P/E Ratio | |
| P/E ratio less than Sector P/E Ratio | |
| P/E ratio that is half the growth rate (or less) | |
| Positive net cash position the past year and most recent quarter | |
| Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
| Positive net income past year and 12 trailing months | |
| Free cash flow ratio greater than 0 and less than 10 |
Small Cap List Algorithm Criteria for GMAB
| Revenue growing by at least 20% average per year over the last 5 years | |
| Market Capitalization under 2 billion | |
| Price to Sales (P/S) ratio 12 trailing months less than Industry P/S ratio twelve trailing months | |
| Price to Sales (P/S) ratio 12 trailing months less than Sector P/S ratio twelve trailing months | |
| Net Income past year > Net Income prior year OR Net Income 12 trailing months > Net Income prior year OR Net Income 12 trailing months > Net Income past year |
Dividend List Algorithm Criteria for GMAB
| Declared an ex-dividend date | |
| Forward annual dividend rate greater than 2 | |
| Positive net cash position the past year and most recent quarter | |
| Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
| Current ratio most recent quarter greater than 2 |
Bonus Criteria for GMAB
| P/E ratio less than five-year Average P/E ratio | |
| Last Price to 52 Week Low Ratio Less Than 1 | |
| Total Cash Per Share > Last Day Price | |
| P/S Ratio < 1 | |
| P/B Ratio < 1 |
Latest News for for GMAB
Financial Details for GMAB
Company Overview |
|
|---|---|
| Ticker | GMAB |
| Company Name | Genmab |
| Country | USA |
| Description | Genmab A / S develops antibody therapies for the treatment of cancer and other diseases mainly in Denmark. The company is headquartered in Copenhagen, Denmark. |
| Sector Name | LIFE SCIENCES |
| Industry Name | PHARMACEUTICAL PREPARATIONS |
| Most Recent Quarter | 12/31/2023 |
| Next Earnings Date | 5/2/2024 |
Stock Price History |
|
| Last Day Price | 28.47 |
| Last Day Price Updated | 4/25/2024 1:41:19 AM EST |
| Last Day Volume | 456,129 |
| Average Daily Volume | 417,792 |
| 52-Week High | 42.72 |
| 52-Week Low | 26.32 |
| Last Price to 52 Week Low | 8.17% |
Valuation Measures |
|
| Trailing PE | 30.38 |
| Industry PE | 101.20 |
| Sector PE | 61.73 |
| 5-Year Average PE | 25.71 |
| Free Cash Flow Ratio | 1.24 |
| Industry Free Cash Flow Ratio | 12.66 |
| Sector Free Cash Flow Ratio | 30.74 |
| Current Ratio Most Recent Quarter | 13.34 |
| Total Cash Per Share | 22.92 |
| Book Value Per Share Most Recent Quarter | 483.85 |
| Price to Book Ratio | 4.19 |
| Industry Price to Book Ratio | 5.66 |
| Sector Price to Book Ratio | 22.08 |
| Price to Sales Ratio Twelve Trailing Months | 1.17 |
| Industry Price to Sales Ratio Twelve Trailing Months | 5.48 |
| Sector Price to Sales Ratio Twelve Trailing Months | 5.16 |
Share Statistics |
|
| Total Shares Outstanding | 648,539,000 |
| Market Capitalization | 18,463,905,330 |
| Institutional Ownership | N/A |
Dividends |
|
| Ex-Dividend Date | N/A |
| Last Dividend Amount | 0.00 |
| Current Dividend Amount | 0.00 |
| Dividend Aristocrat? | False |
| Trailing Annual Dividend Rate | 0.00 |
| Trailing Annual Dividend Yield | 0.00% |
| Forward Annual Dividend Rate | 0.00 |
| Forward Annual Dividend Yield | 0.00% |
| 5-Year Dividend Payments Count | 0 |
| 3-Year Average Dividend Yield | 0.00% |
| 5-Year Average Dividend Yield | 0.00% |
| 1-Year Dividend Growth Rate Percentage | 0.00% |
| 3-Year Dividend Growth Rate Percentage | 0.00% |
| 5-Year Dividend Growth Rate Percentage | 0.00% |
| All-Time Dividend Growth Rate Percentage | 0.00% |
| Dividend Payout Ratio | N/A |
Income Statement |
|
| Quarterly Earnings Growth YOY | 24.60% |
| Annual Earnings Growth | -20.18% |
| Reported EPS 12 Trailing Months | 0.94 |
| Reported EPS Past Year | 0.00 |
| Reported EPS Prior Year | 0.96 |
| Net Income Twelve Trailing Months | 4,352,000,000 |
| Net Income Past Year | 4,352,000,000 |
| Net Income Prior Year | 5,452,000,000 |
| Quarterly Revenue Growth YOY | -8.90% |
| 5-Year Revenue Growth | 40.35% |
Balance Sheet |
|
| Total Cash Most Recent Quarter | 14,867,000,000 |
| Total Cash Past Year | 14,867,000,000 |
| Total Cash Prior Year | 9,893,000,000 |
| Net Cash Position Most Recent Quarter | 14,867,000,000 |
| Net Cash Position Past Year | 14,867,000,000 |
| Long Term Debt Past Year | 0 |
| Long Term Debt Prior Year | 0 |
| Total Debt Most Recent Quarter | 0 |
| Equity to Debt Ratio Past Year | 1.00 |
| Equity to Debt Ratio Most Recent Quarter | 1.00 |
| Total Stockholder Equity Past Year | 31,610,000,000 |
| Total Stockholder Equity Prior Year | 27,441,000,000 |
| Total Stockholder Equity Most Recent Quarter | 31,610,000,000 |
Options |
|
| Put/Call Ratio | 0.89 |
| Has Options | False |
| Liquidity Rating | None |
Technical Analysis |
|
| Yahoo Finance Chart | Yahoo Finance Chart |
| MACD | -0.28 |
| MACD Signal | -0.16 |
| 20-Day Bollinger Lower Band | 27.15 |
| 20-Day Bollinger Middle Band | 29.66 |
| 20-Day Bollinger Upper Band | 32.18 |
| Beta | 0.78 |
| RSI | 42.11 |
| 50-Day SMA | 33.72 |
| 200-Day SMA | 36.99 |
System |
|
| Modified | 4/25/2024 1:42:05 AM EST |